Daraasada bukaan-socodka waxaa loogu talagalay in lagu qiimeeyo badbaadada iyo waxtarka LNK01001 ee maadooyinka leh rheumatoid arthritis-ku dhexdhexaad ah ama daran kuwaas oo leh jawaab celin liidata ama dulqaad la'aanta daawooyinka caadiga ah ee wax-ka-beddelka daawooyinka antirheumatic (csDMARDs).
LNK01001 waa daawadii ugu horeysay ee hal abuur leh oo ay samaysay Lynk Pharmaceuticals, waana ka hortag kinase ah oo la xushay oo loogu talagalay daawaynta cudurada difaaca jirka. Markii hore, LNK01001 waxay dhamaystirtay daraasaadka kiliinikada ee Wajiga I ee maadooyinka caafimaadka qaba xagaaga sanadkan Shiinaha iyo Australia iyo Japan, oo ay kafaala qaadeen Lynk Pharmaceuticals iyo lamaanaheeda Mareykanka, siday u kala horreeyaan. Natiijooyinku waxay muujiyeen in dawadu ay badbaado tahay oo si wanaagsan loo dulqaadan karo. Intaa waxaa dheer, LNK01001 waxaa ansixiyay Maamulka Alaabada Caafimaadka Qaranka ee Shiinaha (NMPA) ee qiimeynta kiliinikada ee calaamadaha cusub - ankylosing spondylitis (AS) iyo dermatitis atopic (AD).
Professor Xiaofeng Zeng waa baaraha maamulaha daraasaddan iyo agaasimaha Waaxda Rheumatology iyo Immunology ee Isbitaalka Peking Union Medical College iyo Akadeemiyada Shiinaha ee Sayniska Caafimaadka.
